A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Clinical trial NCT06292013 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06292013
Sponsor: Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)

Start date: 2024-03-05
Primary completion: 2029-03-01
Enrollment: 17300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.